S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Lexicon PharmaceuticalsChimerixGlycoMimeticsBioXcel TherapeuticsKala Pharmaceuticals
SymbolNASDAQ:LXRXNASDAQ:CMRXNASDAQ:GLYCNASDAQ:BTAINASDAQ:KALA
Price Information
Current Price$3.30$1.46$5.12$5.23$3.38
52 Week RangeBuyHoldBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$6.75$4.00$16.00$22.33$21.80
% Upside from Price Target104.55% upside173.97% upside212.50% upside327.02% upside544.97% upside
Trade Information
Market Cap$340.06 million$89.15 million$204.30 million$84.63 million$118.34 million
Beta0.911.42.72.962.14
Average Volume1,297,117451,001461,18267,245248,799
Sales & Book Value
Annual Revenue$63.21 million$7.22 million$20,000.00N/AN/A
Price / Sales5.5512.3911,057.41N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.25) per share$3.50 per share$4.76 per share$2.49 per share$3.11 per share
Price / Book-13.200.421.08N/AN/A
Profitability
Net Income$-120,550,000.00$-69,470,000.00$-48,270,000.00$-19,270,000.00$-66,740,000.00
EPS($1.14)($1.43)($1.18)($1.32)($2.48)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-208.07%-729.02%N/AN/AN/A
Return on Equity (ROE)N/A-38.70%-27.88%-77.72%-117.68%
Return on Assets (ROA)-32.82%-36.02%-26.48%-66.59%-52.43%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.02%0.04%1.16%
Current Ratio5.45%11.71%17.54%3.93%7.50%
Quick Ratio5.26%11.71%17.54%3.93%7.04%
Ownership Information
Institutional Ownership Percentage98.87%63.43%N/A20.39%68.67%
Insider Ownership Percentage6.40%9.40%26.80%64.80%30.77%
Miscellaneous
Employees202825018130
Shares Outstanding106.27 million61.27 million43.19 million15.73 million34.01 million
Next Earnings Date11/7/2019 (Estimated)11/14/2019 (Estimated)11/1/2019 (Estimated)11/8/2019 (Estimated)11/14/2019 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
 Lexicon PharmaceuticalsChimerixGlycoMimeticsBioXcel TherapeuticsKala Pharmaceuticals

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel